Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Lockheed Martin Corporation (LMT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Lockheed Martin Corporation — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.76 (market cap $4.49B), while Lockheed Martin Corporation trades at $530.14 (market cap $123.44B). The key difference: Lockheed Martin Corporation is far larger — about 27.5× ACADIA Pharmaceuticals Inc.'s market cap, and Lockheed Martin Corporation pays a 2.58% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | LMT | |
|---|---|---|
Market Cap | $4.49B | $123.44B |
Sector | Health | Industrials |
52-Week High | $28.06 | $676.70 |
52-Week Low | $20.06 | $410.74 |
Enterprise Value | $3.69B | $142.24B |
Dividend Yield | — | 2.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Lockheed Martin (LMT) trades at $535.38, down 1.89% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $627.50. Recent financials show revenue growth to $75.05B in 2025, though net income margin declined to 6.38%. The company announced a $3.45B acquisition of Ultra Maritime to expand naval defense capabilities, and a dividend of $3.45 is scheduled for payment in June 2026.
LMT offers stability through government contracts and dividend growth, but faces risks from execution on recent acquisitions and margin pressure. Analyst sentiment is positive with 57% buy ratings, yet recent earnings misses and rising debt levels warrant caution. The stock presents a long-term opportunity in defense, balanced by near-term operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Lockheed Martin Corporation
Lockheed Martin is the largest defense contractor globally and has dominated the Western market for high-end fighter aircraft since the F-35 program was awarded in 2001. Lockheed's largest segment is aeronautics, which is dominated by the massive F-35 program. Lockheed's remaining segments are rotary and mission systems, which is mainly the Sikorsky helicopter business.
Read more on LMT →
